Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $4.5 to $...
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target f...
Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and servic...
Health Catalyst (NASDAQ:HCAT) sees Q4 sales of $73.500 million vs $76.016 million analyst estimate.
Health Catalyst (NASDAQ:HCAT) affirms FY2025 sales outlook from $310.000 million to $310.000 million vs $312.152 million estimate.
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is ...
Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:HCAT) with a In-Line and lowers the price ta...
Keybanc analyst Scott Schoenhaus maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from ...
